Pfizer anticipates revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization. See why ...

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), ...

Editorial writers explain these public health issues.

Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.